• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, October 4, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

New compounds block master regulator of cancer growth, metastasis

Bioengineer by Bioengineer
January 7, 2020
in Chemistry
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Photo by L. Brian Stauffer

CHAMPAIGN, Ill. — Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM1, a transcription factor that regulates the activity of dozens of genes. The new compounds suppress tumor growth in human cells and in mouse models of several types of human breast cancer.

The researchers report their findings in the journal NPJ Breast Cancer.

FOXM1 is a naturally occurring protein that ramps up the expression of genes that are important to cell proliferation and development. It plays an important role during early development, but normally is present only at very low levels in adult tissues.

The researchers focused on FOXM1 because it is found in higher abundance in cancer cells than in healthy human cells, said Benita Katzenellenbogen, a University of Illinois professor of molecular and integrative physiology who led the study with U. of I. chemistry professor John Katzenellenbogen and life sciences research specialist Yvonne Ziegler.

“FOXM1 is a key factor that makes breast cancer and many other cancers more aggressive and more difficult to treat,” Benita Katzenellenbogen said. “Because it is a master regulator of cancer growth and metastasis, there has been great interest in developing compounds that would be effective in blocking it.”

So far, no successful drug agents have been developed to reduce the effects of FOXM1, John Katzenellenbogen said.

“There are reports of other inhibitors of FOXM1, but these are generally less potent and do not work well in the body,” he said. “Our compounds have good anti-tumor activity in animal models. They behave well in vivo and have long half-lives in the blood. Some work well when given orally, which is desirable for ultimate patient use.”

The researchers developed the new drugs by analyzing the properties of various compounds in a chemical library of potentially therapeutic agents. They selected those that reduced breast cancer cell proliferation and inhibited the expression of genes known to be regulated by FOXM1.

The team then modified the compounds to enhance their inhibition of FOXM1 and increase their cellular potency. Three of the tested compounds performed best.

“We found that these compounds inhibit the growth of breast cancer cells that represent the major subtypes of breast cancers, including estrogen receptor-positive, HER2-positive and triple-negative breast cancers,” Benita Katzenellenbogen said. “They also block the growth of human breast tumors in mouse models.”

The research is promising, but preliminary, the scientists said. Full development of new anti-cancer drug agents can take more than a decade from this stage of discovery.

“Because cancers are often treated with a combination of drugs, we are exploring how our FOXM1 inhibitors might be combined with other standard-of-care agents to improve cancer treatment,” Benita Katzenellenbogen said.

###

The Breast Cancer Research Foundation, the Julius and Mary Landfield Cancer Research Fund, the National Institutes of Health and the National Institute of Food and Agriculture at the U.S. Department of Agriculture supported this research.

Editor’s notes:

To reach Benita Katzenellenbogen, call 217-333-9769; email [email protected].

To reach John Katzenellenbogen, call 217-333-6310; email [email protected].

The paper “Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds” is available online and from the U. of I. News Bureau.

Media Contact
Diana Yates
[email protected]
217-333-5802

Original Source

https://news.illinois.edu/view/6367/805303

Related Journal Article

http://dx.doi.org/10.1038/s41523-019-0141-7

Tags: Breast CancercancerGenesMedicine/HealthPharmaceutical ChemistryPharmaceutical Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Electron Donor–Acceptor Complexes Enable Asymmetric Photocatalysis

Electron Donor–Acceptor Complexes Enable Asymmetric Photocatalysis

October 4, 2025
AI Advances Enhance Sustainable Recycling of Livestock Waste

AI Advances Enhance Sustainable Recycling of Livestock Waste

October 3, 2025

Crafting Yogurt Using Ants: A Scientific Innovation

October 3, 2025

Pd-Catalyzed Synthesis of E/Z Trisubstituted Cycloalkenes

October 3, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    93 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    89 shares
    Share 36 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    68 shares
    Share 27 Tweet 17

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Enhances Prognosis in Esophageal Adenocarcinoma via Hyperspectral Imaging

Ginsenoside Rf Enhances Glucose Metabolism in Insulin Resistance

Discovery of MrSTP20: Sugar Transporter in Salt Stress

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.